Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis
- 13 March 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (6) , 2292-2304
Abstract
Aims: To conduct a systematic review and meta‐analysis with the aim of synthesizing existing data on the efficacy and safety of topiramate as an adjunctive treatment for reducing second‐generation antipsychotic (SGA)‐associated weight gain in children aged 4–18 years. Methods: We conducted a comprehensive search of PubMed, Embase, PsychNet and Web of Science from time of their inception up to 12 February 2024, including randomized controlled trials that compared SGA treatment with and without topiramate co‐administration in children. The primary outcomes were changes in body weight and body mass index (BMI). Heterogeneity was assessed using I 2 statistics. Results: This systematic review included five randomized trials, totalling 139 participants (43.9% female; mean [SD] age 11.9 [3.5] years). Four of these trials were included in the meta‐analysis, comprising 116 subjects. We found that topiramate was significantly effective both in reducing SGA‐associated weight gain, with a mean difference of −2.80 kg (95% confidence interval [CI] −5.28 to −0.31; p = 0.037, I 2 = 86.7%) and a standardized mean difference (SMD) of −1.33 (95% CI −2.14 to −0.51; p = 0.014, I 2 = 31.7%), and in reducing BMI change compared to placebo (SMD −1.90, 95% CI −3.09 to −0.70; p = 0.02, I 2 = 0%). Sedation risk was lower with topiramate than with placebo (odds ratio 0.19, 95% CI 0.11–0.32; p < 0.01, I 2 = 0%). No significant differences were found in dropouts, any other side effects, and metabolic parameters, such as triglycerides, total cholesterol, low‐density lipoprotein, high‐density lipoprotein, and glucose. None of the included studies reported assessments on cognitive side effects. Conclusion: This meta‐analysis suggests that topiramate is an effective and safe option for mitigating SGA‐associated weight gain in children.Keywords
This publication has 39 references indexed in Scilit:
- What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelinesJournal of Affective Disorders, 2022
- Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysisEuropean Neuropsychopharmacology, 2018
- The prevalence, risk factors and clinical correlates of obesity in Chinese patients with schizophreniaPsychiatry Research, 2017
- The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activityEuropean Journal of Clinical Nutrition, 2013
- Association of All-Cause Mortality With Overweight and Obesity Using Standard Body Mass Index CategoriesJAMA, 2013
- Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practiceEuropean Psychiatry, 2011
- Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorderProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
- The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
- Metabolic and Cardiovascular Adverse Events Associated With Antipsychotic Treatment in Children and AdolescentsArchives of Pediatrics & Adolescent Medicine, 2008
- Imputing missing standard deviations in meta-analyses can provide accurate resultsJournal of Clinical Epidemiology, 2006